Secondary breast angiosarcomas are a well-known entity generally characterized by a poor outcome, especially in patients with advanced disease. Among the drugs with demonstrated activity, taxane derivatives are one of the most effective histology-driven treatments against angiosarcomas. We report two cases of secondary breast angiosarcoma, both characterized by a very peculiar behavior towards paclitaxel. Both patients showed local recurrence of angiosarcoma after primary surgery, and they achieved complete remission following treatment with weekly paclitaxel. When a locoregional recurrence was observed as a result of a brief treatment interruption or a treatment delay, a new complete remission was rapidly achieved with the resumption of the drug, without evidence of any significant adverse effects.
AbbottR.PalmieriC.Angiosarcoma of the breast following surgery and radiotherapy for breast cancer. Nat Clin Pract Oncol.2008; 5(12): 727–736.
2.
SeinenJ.M.StyringE.VerstappenV.Radiation-associated angiosarcoma after breast cancer: high recurrence rate and poor survival despite surgical treatment with R0 resection. Ann Surg Oncol.2012, 19(8): 2700–2706.
3.
ToescaA.SpitaleriG.DePasT.Sarcoma of the breast: outcome and reconstructive options. Clin BreastCancer.2012; 12(6): 438–44.
4.
FataF.O'ReillyE.IlsonD.Paclitaxel in the treatment of patients with angiosarcoma of the scalp or face. Cancer.1999; 86(10): 2034–2037.
5.
SkubitzK.M.HaddadP.A.Paclitaxel and pegylated-liposomal doxorubicin are both active in angiosarcoma. Cancer.2005; 104(2): 361–366.
6.
FuryM.G.AntonescuC.R.Van ZeeK.J.BrennanM.F.MakiR.G.A 14-year retrospective review of angiosarcoma: clinical characteristics, prognostic factors, and treatment outcomes with surgery and chemotherapy. Cancer J.2005; 11(3): 241–247.
7.
YamadaM.HattaN.MizunoM.OishiN.TakeharaK.Weekly low-dose docetaxel in the treatment of lung metastases from angiosarcoma of the head. Br J Dermatol.2005; 152: 811–812.
8.
MathewP.Vakar-LopezF.TroncosoP.Protracted remission of metastatic epithelioid angiosarcoma with weekly infusion of doxorubicin, paclitaxel, and cisplatin. Lancet Oncol.2006; 7(1): 92–93.
9.
StacchiottiS.PalassiniE.SanfilippoR.Gemcitabine in advanced angiosarcoma: a retrospective case series analysis from the Italian Rare Cancer Network. Ann Oncol.2012; 23(2): 501–508.
10.
ErikssonM.Histology-driven chemotherapy of soft-tissue sarcoma. Ann Oncol.2010; 21(Suppl 7): vii270–vii276.
11.
GambiniD.VisintinR.LocatelliE.Paclitaxel-dependent prolonged and persistent complete remission four years from first recurrence of secondary breast angiosarcoma. Tumori.2009; 95(6): 828–831.
12.
ChiarelliA.BocconeP.GoiaF.Gingival metastasis of a radiotherapy-induced breast angiosarcoma: diagnosis and multidisciplinary treatment achieving a prolonged complete remission. Anticancer Drugs.2012; 23(10): 1112–1117.
13.
ManoM.S.FraserG.KerrJ.Radiation-induced angiosarcoma of the breast shows major response to docetaxel after failure of anthracycline-based chemotherapy. Breast.2006; 15(1): 117–118.
14.
PenelN.BuyB.N.BayJ.O.Phase II trial of weekly paclitaxel for unresectable angiosarcoma: the ANGIOTAX Study. J Clin Oncol.2008; 26(32): 5269–5274.
15.
HoffmannG.MylonasI.Therapy of radiation-induced angiosarcoma of the breast in an elderly patient. Arch Gynecol Obstet.2013; 287(4): 827–831.
16.
NakamuraR.NagashimaT.SakakibaraM.Angiosarcoma arising in the breast following breast-conserving surgery with radiation for breast carcinoma. Breast Cancer.2007; 14(2): 245–249.
17.
HuiA.HendersonM.SpeakmanD.SkandarajahA.Angiosarcoma of the breast: a difficult surgical challenge. Breast.2012; 21(4): 584–589.
18.
PeramiquelL.BarnadasM.A.SanchoJ.Angiosarcoma in an irradiated breast: a case description. Actas Dermosifiliogr.2005; 96(9): 602–606.
19.
Perez-RuizE.RibellesN.Sanchez-MunozA.RomanA.MarquezA.Response to paclitaxel in a radiotherapy-induced breast angiosarcoma. Acta Oncol.2009; 48(7): 1078–1079.
20.
TomaselloL.GardinG.BoccardoF.Secondary breast angiosarcoma: lethal response to anti-angiogenic therapy with paclitaxel chemotherapy. A case report. Anticancer Res.2006; 26(6C): 4775–4777.
21.
GennaroM.ValeriB.CasaliniP.Angiosarcoma of the breast and vascular endothelial growth factor receptor. Tumori.2010; 96(6): 930–935.
22.
AzzaritiA.PorcelliL.MangiaA.Irradiation-induced angiosarcoma and anti-angiogenic therapy: a therapeutic hope?Exp Cell Res.2014; 321(2): 240–247.
23.
Ray-CoquardI.ItalianoA.BompasE.; French Sarcoma Group (GSF/GETO). Sorafenib for patients with advanced angiosarcoma: a phase II trial from the French Sarcoma Group (GSF/GETO). Oncologist.2012; 17(2): 260–266.
24.
OnoS.TaniokaM.FujisawaA.TanizakiH.MiyachiY.MatsumuraY.Angiosarcoma of the scalp successfully treated with a single therapy of sorafenib. Arch Dermatol.2012; 148(6): 683–685.
25.
CasaliP.G.Histology-and non-histology-driven therapy for treatment of soft tissue sarcomas. Ann Oncol.2012; 23(Suppl 10): xl67–xl69.
26.
van derGraafW.T.BlayJ.Y.ChawlaS.P.; EORTC Soft Tissue and Bone Sarcoma Group; PALETTE Study Group. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet.2012; 379(9829): 1879–1886.
27.
SleijferS.Ray-CoquardI.PapaiZ.Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European Organisation for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (EORTC study 62043). J Clin Oncol.2009; 27(19): 3126–3132.
28.
LauD.GuoL.GandaraD.YoungL.J.XueL.Is inhibition of cancer angiogenesis and growth by paclitaxel schedule dependent?Anticancer Drugs.2004; 15(9): 871–875.
29.
BocciG.Di PaoloA.DanesiR.The pharmacological bases of the antiangiogenic activity of paclitaxel. Angiogenesis.2013; 16(3): 481–492.
30.
MoesJ.KoolenS.HuitemaA.SchellensJ.BeijnenJ.NuijenB.Development of an oral solid dispersion formulation for use in low-dose metronomic chemotherapy of paclitaxel. Eur J Pharm Biopharm.2013; 83(1): 87–94.
